NCT07017270RecruitingPhase 4
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
Source: ClinicalTrials.gov · Last updated 26 Jun 2026
Brief summary (registry, in English)
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 24 Apr 2025
- Start date
- 27 Nov 2025
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Unity Health Toronto
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT07017270
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 27 Nov 2025 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of a GLP-1-RA within 30 days prior to screening
- Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months
Other illness
- Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)
- Known hypersensitivity to GLP-1-RA
Other
- Type 1 DM
- Confirmed pregnancy, women of childbearing potential
- Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA
Who the study is looking for
- Age ≥ 18
- Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days
- confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin.
- Ability to provided informed consent or through their substitute decision maker
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Unity Health Toronto Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.